相似文献
1
Regulatory T cells as therapeutic targets in rheumatoid arthritis.
Nat Rev Rheumatol. 2009 Oct;5(10):560-5. doi: 10.1038/nrrheum.2009.183.
2
Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.
Arthritis Rheum. 2010 Jan;62(1):53-63. doi: 10.1002/art.25037.
3
Function and Role of Regulatory T Cells in Rheumatoid Arthritis.
Front Immunol. 2021 Apr 1;12:626193. doi: 10.3389/fimmu.2021.626193. eCollection 2021.
4
The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics.
Curr Opin Rheumatol. 2013 Mar;25(2):260-7. doi: 10.1097/BOR.0b013e32835d0ee4.
5
Regulatory T cells in patients with early untreated rheumatoid arthritis: Phenotypic changes in the course of methotrexate treatment.
Biochimie. 2020 Jul;174:9-17. doi: 10.1016/j.biochi.2020.03.014. Epub 2020 Apr 7.
6
Sirolimus selectively increases circulating Treg cell numbers and restores the Th17/Treg balance in rheumatoid arthritis patients with low disease activity or in DAS28 remission who previously received conventional disease-modifying anti-rheumatic drugs.
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):58-66. Epub 2019 Apr 29.
7
Maresin 1 improves the Treg/Th17 imbalance in rheumatoid arthritis through miR-21.
Ann Rheum Dis. 2018 Nov;77(11):1644-1652. doi: 10.1136/annrheumdis-2018-213511. Epub 2018 Jul 25.
8
CD4+CD25(high)CD127(low/-) Treg cell frequency from peripheral blood correlates with disease activity in patients with rheumatoid arthritis.
J Rheumatol. 2011 Dec;38(12):2517-21. doi: 10.3899/jrheum.110283. Epub 2011 Sep 15.
9
Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy.
Arthritis Rheum. 2012 Oct;64(10):3129-38. doi: 10.1002/art.34565.
10
Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.
Rheumatology (Oxford). 2011 Oct;50(10):1814-22. doi: 10.1093/rheumatology/ker183. Epub 2011 Jul 26.
引用本文的文献
1
Current state and future directions of basic research in rheumatoid arthritis.
J Rheum Dis. 2025 Jul 1;32(3):166-181. doi: 10.4078/jrd.2024.0151. Epub 2025 Feb 6.
2
A new 3-arylbenzofuran derivative EIE-2 reestablishes Treg-dependent tolerance in rheumatoid arthritis by targeting on Syk induced mTOR and PKCθ imbalance.
Front Immunol. 2025 May 21;16:1524491. doi: 10.3389/fimmu.2025.1524491. eCollection 2025.
3
Microbiome's role in musculoskeletal health through the gut-bone axis insights.
Gut Microbes. 2024 Jan-Dec;16(1):2410478. doi: 10.1080/19490976.2024.2410478. Epub 2024 Oct 10.
4
The Application Potential of the Regulation of Tregs Function by Irisin in the Prevention and Treatment of Immune-Related Diseases.
Drug Des Devel Ther. 2024 Jul 16;18:3005-3023. doi: 10.2147/DDDT.S465713. eCollection 2024.
5
Unveiling new genetic insights in rheumatoid arthritis for drug discovery through Taxonomy3 analysis.
Sci Rep. 2024 Jun 19;14(1):14153. doi: 10.1038/s41598-024-64970-0.
6
Targeting Lymph Nodes for Systemic Immunosuppression Using Cell-Free-DNA-Scavenging And cGAS-Inhibiting Nanomedicine-In-Hydrogel for Rheumatoid Arthritis Immunotherapy.
Adv Sci (Weinh). 2023 Sep;10(26):e2302575. doi: 10.1002/advs.202302575. Epub 2023 Jul 12.
7
High-throughput Treg cell receptor sequencing reveals differential immune repertoires in rheumatoid arthritis with kidney deficiency.
PeerJ. 2023 Feb 2;11:e14837. doi: 10.7717/peerj.14837. eCollection 2023.
8
Short term, low dose alpha-ketoglutarate based polymeric nanoparticles with methotrexate reverse rheumatoid arthritis symptoms in mice and modulate T helper cell responses.
Biomater Sci. 2022 Nov 22;10(23):6688-6697. doi: 10.1039/d2bm00415a.
9
Efficacy and safety of low-dose interleukin-2 in combination with methotrexate in patients with active rheumatoid arthritis: a randomized, double-blind, placebo-controlled phase 2 trial.
Signal Transduct Target Ther. 2022 Mar 7;7(1):67. doi: 10.1038/s41392-022-00887-2.
10
Immunomodulatory Effects of Curcumin in Rheumatoid Arthritis: Evidence from Molecular Mechanisms to Clinical Outcomes.
Rev Physiol Biochem Pharmacol. 2021;179:1-29. doi: 10.1007/112_2020_54.
本文引用的文献
1
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.
Nat Immunol. 2009 Sep;10(9):1000-7. doi: 10.1038/ni.1774. Epub 2009 Jul 26.
2
Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin.
PLoS One. 2009 Jun 22;4(6):e5994. doi: 10.1371/journal.pone.0005994.
3
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease.
Blood. 2009 Jul 23;114(4):891-900. doi: 10.1182/blood-2009-01-197178. Epub 2009 Jun 2.
4
Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation.
Blood. 2009 May 28;113(22):5689-91. doi: 10.1182/blood-2009-02-206359.
5
FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning.
Immunol Res. 2009;44(1-3):179-84. doi: 10.1007/s12026-009-8112-y.
6
Human T regulatory cell therapy: take a billion or so and call me in the morning.
Immunity. 2009 May;30(5):656-65. doi: 10.1016/j.immuni.2009.04.006.
7
Plasticity of CD4+ T cell lineage differentiation.
Immunity. 2009 May;30(5):646-55. doi: 10.1016/j.immuni.2009.05.001.
8
Mechanisms of foxp3+ T regulatory cell-mediated suppression.
Immunity. 2009 May;30(5):636-45. doi: 10.1016/j.immuni.2009.04.010.
9
Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.
Immunity. 2009 Jun 19;30(6):899-911. doi: 10.1016/j.immuni.2009.03.019. Epub 2009 May 21.
10
IL-2 and its high-affinity receptor: genetic control of immunoregulation and autoimmunity.
Semin Immunol. 2009 Dec;21(6):363-71. doi: 10.1016/j.smim.2009.04.004. Epub 2009 May 15.
Zotero 插件